HighTower Advisors’s Evolent Health EVH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-70,211
Closed -$2.31M 3761
2024
Q1
$2.31M Sell
70,211
-43,975
-39% -$1.4M ﹤0.01% 1357
2023
Q4
$3.76M Buy
114,186
+105,459
+1,208% +$2.98M 0.01% 1109
2023
Q3
$237K Sell
8,727
-243
-3% -$6.75K ﹤0.01% 2779
2023
Q2
$271K Sell
8,970
-550
-6% -$17.8K ﹤0.01% 2633
2023
Q1
$308K Buy
+9,520
New +$301K ﹤0.01% 2435
2022
Q3
Sell
-6,596
Closed -$201K 3217
2022
Q2
$201K Sell
6,596
-2,552
-28% -$74.4K ﹤0.01% 2635
2022
Q1
$296K Buy
+9,148
New +$240K ﹤0.01% 2535
2021
Q4
Sell
-7,130
Closed -$222K 3347
2021
Q3
$222K Buy
+7,130
New +$171K ﹤0.01% 2633
2020
Q2
Sell
-21,401
Closed -$102K 2458
2020
Q1
$102K Buy
21,401
+10,555
+97% +$94.3K ﹤0.01% 1935
2019
Q4
$84K Sell
10,846
-9,355
-46% -$76K ﹤0.01% 2091
2019
Q3
$136K Buy
20,201
+3,747
+23% +$26.9K ﹤0.01% 2132
2019
Q2
$124K Buy
16,454
+522
+3% +$6.18K ﹤0.01% 2137
2019
Q1
$203K Buy
15,932
+1,996
+14% +$31.6K ﹤0.01% 1955
2018
Q4
$283K Buy
13,936
+5,552
+66% +$128K ﹤0.01% 1641
2018
Q3
$240K Buy
+8,384
New +$200K ﹤0.01% 1844

Other funds holding EVH

HighTower Advisors's EVH Position: Q2 2024 in Review

HighTower Advisors sold out of Evolent Health (EVH) in Q2 2024, closing a stake of 70,211 shares — an estimated $2.31M sold.

HighTower Advisors first reported a position in EVH in Q3 2018 and held it in 15 quarters. The position peaked at $3.76M in Q4 2023. 243 funds tracked by Wall St. Rank hold EVH as of Q2 2024.

  • HighTower Advisors reported no remaining Evolent Health position as of Q2 2024 after selling out during the quarter.
  • HighTower Advisors sold 70,211 Evolent Health shares in Q2 2024, an estimated $2.31M.
  • HighTower Advisors first reported a position in Evolent Health in Q3 2018 and held it in 15 quarters.
  • HighTower Advisors's Evolent Health position peaked at $3.76M in Q4 2023.
  • 243 funds tracked by Wall St. Rank held Evolent Health as of Q2 2024.

Based on HighTower Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.